Based on the differentially expressed genes in MSS-EO-CRC, we constructed a risk score that significantly correlated with the tumor microenvironment (TME) characterization and showed a promising potential to predict response to anti-programmed death-ligand 1 (PD-L1) immunotherapy. This evidence concerns the gene CD274 and colorectal carcinoma.